Care Bare Rx vs Synergy Rx

Neither Care Bare Rx nor Synergy Rx has an FDA warning letter on record. On brand-name semaglutide pen, Synergy Rx costs $2,472 less a year at standing rates: $499 a month against $705 a month at Care Bare Rx. It is one of two products the two sell at comparable terms.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Care Bare Rx / Synergy Rx

Care Bare Rx logo

Care Bare Rx

9.0/10

Synergy Rx logo

Synergy Rx

7.5/10

FDA warning letters
None on record
None on record
Pharmacy
Lowest standing price
$199/moCompounded semaglutide injection
$199/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026

Neither Care Bare Rx nor Synergy Rx pays us. Links to them earn nothing. Scores: Care Bare Rx 9.0, Synergy Rx 7.5. How we are paid

What the record shows

  1. 01

    Neither Care Bare Rx nor Synergy Rx has an FDA warning letter on record.

  2. 02

    Care Bare Rx names four pharmacies. Synergy Rx names four pharmacies.

  3. 03

    On brand-name semaglutide pen, Synergy Rx costs $2,472 less a year at standing rates: $499 a month against $705 a month at Care Bare Rx. It is one of two products the two sell at comparable terms.

  4. 04

    Only Synergy Rx lists a price for brand-name tirzepatide pen, compounded oral semaglutide and compounded oral tirzepatide.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Care Bare Rx

Synergy Rx

Compounded semaglutide injection

$199/mo

$2,388 a year

$199/mo

$2,388 a year

Compounded tirzepatide injection

$199/moLower

$2,388 a year

$349/mo

$4,188 a year

Brand-name semaglutide pen

$705/mo

$8,460 a year

$499/moLower

$5,988 a year

Brand-name tirzepatide pen
Not sold or not priced

$947/mo

$11,364 a year

Compounded oral semaglutide
Not sold or not priced

$299/mo

$3,588 a year

Compounded oral tirzepatide
Not sold or not priced

$399/mo

$4,788 a year

Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Refunds
Not stated
Non-refundable, all sales final

Read off each seller’s own pages. Care Bare Rx: October 17, 2026. Synergy Rx: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Care Bare Rx

9.0/10
  • $1,800 a year less on compounded tirzepatide injection

The case for Synergy Rx

7.5/10
  • $2,472 a year less on brand-name semaglutide pen
  • Sells brand-name tirzepatide pen and compounded oral semaglutide, which Care Bare Rx does not price

Scores

Care Bare Rx 9.0 · Synergy Rx 7.5 out of 10. Six weighted parts.

Value25%

8.8A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

9.0A
vs
B
9.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Care Bare Rx vs Synergy Rx: questions

Neither Care Bare Rx nor Synergy Rx has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Care Bare Rx names four pharmacies. Synergy Rx names four pharmacies. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Care Bare Rx, by $1,800 a year at standing rates. Care Bare Rx: $199 a month, about $2,388 a year. Synergy Rx: $349 a month, about $4,188 a year.
Neither Care Bare Rx nor Synergy Rx pays us. Links to them earn nothing. Scores: Care Bare Rx 9.0, Synergy Rx 7.5.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks